Skip to main
MGX
MGX logo

Metagenomi Inc (MGX) Stock Forecast & Price Target

Metagenomi Inc (MGX) Analyst Ratings

Based on 3 analyst ratings
Strong Buy
Strong Buy 67%
Buy 33%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Metagenomi Inc has demonstrated a promising capability in its gene editing approach, achieving sustained FVIII levels of 80% over a 19-month period in a non-human primate study, indicating potential efficacy for its treatment candidates. The company's strategic focus on in vivo gene editing for its wholly-owned pipeline, combined with technology out-licensing for ex vivo cell therapy, positions it to maximize its proprietary metagenomics-derived genome editing toolbox. With product candidates targeting critical disorders, such as Hemophilia A and cardiovascular diseases, Metagenomi is well-positioned to address significant unmet medical needs, underscoring a favorable outlook for its stock.

Bears say

Metagenomi Inc reported a significant net loss of $19.9 million, or $0.54 per share, for the second quarter of 2025, highlighting ongoing financial challenges amid their research and development efforts. The company faces multiple risks that may adversely affect its future prospects, including potential delays in clinical assessments and the need to generate favorable clinical data for key programs, particularly in Hemophilia A and TTR. Additionally, there are concerns about long-term dilution risk, which could negatively impact shareholder value as the company attempts to fund its operations and growth initiatives.

Metagenomi Inc (MGX) has been analyzed by 3 analysts, with a consensus rating of Strong Buy. 67% of analysts recommend a Strong Buy, 33% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Metagenomi Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Metagenomi Inc (MGX) Forecast

Analysts have given Metagenomi Inc (MGX) a Strong Buy based on their latest research and market trends.

According to 3 analysts, Metagenomi Inc (MGX) has a Strong Buy consensus rating as of Dec 16, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Metagenomi Inc (MGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.